BIO Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of -728.57%. Bio-Rad Laboratories's return on equity of -29.59% beat Bionano Genomics's return on equity of -158.95%.

Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 32.22%. On the other hand Bionano Genomics has an analysts' consensus of $7.00 which suggests that it could grow by 81.82%. Given that Bionano Genomics has higher upside potential than Bio-Rad Laboratories, analysts believe Bionano Genomics is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.713%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $585.4M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Bio-Rad Laboratories's net income of $64M is higher than Bionano Genomics's net income of -$44.2M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.66x versus 0.09x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of 2.17%. Bio-Rad Laboratories's return on equity of -29.59% beat Bruker's return on equity of 4.53%.

Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 32.22%. On the other hand Bruker has an analysts' consensus of $56.59 which suggests that it could grow by 39.7%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.49% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories quarterly revenues are $585.4M, which are smaller than Bruker quarterly revenues of $801.4M. Bio-Rad Laboratories's net income of $64M is higher than Bruker's net income of $17.4M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 77.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.66x versus 1.77x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of 0.07%. Bio-Rad Laboratories's return on equity of -29.59% beat Harvard Bioscience's return on equity of -18.36%.

Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 32.22%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1377.35%. Given that Harvard Bioscience has higher upside potential than Bio-Rad Laboratories, analysts believe Harvard Bioscience is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $585.4M, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Bio-Rad Laboratories's net income of $64M is higher than Harvard Bioscience's net income of $18K. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.66x versus 0.14x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 10.93% compared to Bio-Rad Laboratories's net margin of 28.26%. Bio-Rad Laboratories's return on equity of -29.59% beat ResMed's return on equity of 25.76%.

Bio-Rad Laboratories has a consensus price target of $318.67, signalling upside risk potential of 32.22%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 8.8%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.

Bio-Rad Laboratories has a beta of 0.999, which suggesting that the stock is 0.087999999999999% less volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories quarterly revenues are $585.4M, which are smaller than ResMed quarterly revenues of $1.3B. Bio-Rad Laboratories's net income of $64M is lower than ResMed's net income of $365M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while ResMed's PE ratio is 27.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.66x versus 7.14x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.